Novacyt S.A. (Novacyt, the Company or the Group) Full Year 2

Full year revenue and EBITDA in line with guidance Remain focused on post-COVID-19 growth strategy to become a leading global clinical diagnostics company in infectious diseases Regulatory News: Novacyt

Related Keywords

United Kingdom , France , Freddie Barnfield Duncan Monteith , Foster Mitchell Alex Shaw , Vadim Alexandre Rob Rees , Matthew Johnson Charlie Bouverat , James Mccarthy , Durgetto Yannick Petit , James Wakefield , Sp Angel Corporate Finance , Novacyt Group , Consulting International , European Union Withdrawal , Regulatory Information Service , Microgen Bioproducts , Market Abuse Regulation , European Union , Non Executive Chairman , Acting Chief Executive Officer , Nominated Adviser , Johnson Charlie Bouverat , Corporate Finance , Alexandre Rob Rees , Corporate Broking , Joint Broker , Black Freddie Barnfield Duncan Monteith , French Listing Sponsor , Novacyt , Company , Group , Bull , Ear , 022 , Trading , Update ,